Et Cancers(和癌症)研究综述Et Cancers 和癌症 - Germline TP53 pathogenic variants are rare but associated with a high risk of cancer; they are often identified in the context of clinically diagnosed Li–Fraumeni syndrome predisposing to a range of young onset cancers including sarcomas and breast cancer.  However, known tumor suppressor driver genes regulated by methylation are relatively infrequently altered in target cancers.  Hematopoietic Stem Cell Transplant: Although there is some evidence for an increase in CC in large cohort studies of these patients, conflicting results may reflect that many patients did not survive long enough to evaluate the incidence of slow-growing or delayed-onset cancers.  Almost all early‐onset cancers were sporadic (98% or more).  Therefore, Mcl-1 inhibition could serve as a strategy to target cancers that require Mcl-1 to evade apoptosis.  Conventional antitumor drugs cannot specifically target cancers and result in serious side effects.  Apart from the higher degree of CIN in left-sided early-onset cancers, differential copy number alterations were also observed.  En depistage, la sensibilite des tests HPV HR est de 63 % a 98 % alors que celle du FCU est seulement de 38 % a 65 % pour la detection des LIEHG+ (LIEHG et cancers invasifs).  Cancer-related aptamers can be used for tumor-targeted drug delivery, such as to deliver diagnostic and therapeutic radionuclides to target cancers.  We designed aptamer-siRNA chimeras that can specifically target cancers expressing EpCAM, a stem cell marker and deliver the specific siRNA required for therapy response.  Compte-tenu des liens etroits entre myosites et cancers a travers les syndromes paraneoplasiques, et de la generalisation de l’immunotherapie en oncologie, une bonne coordination des soins a travers un reseau pluridisciplinaire d’experts, integrant la medecine interne et les centres regionaux de pharmacovigilance, parait essentielle pour une meilleure prise en charge de ces malades.  4% of patients with TC and half of them were late onset cancers not common in the population in their 40s.  Li–Fraumeni syndrome (LFS) is an autosomal dominant condition associated with a high risk of a broad range of childhood- and adult-onset cancers.  Introduction La relation entre maladies auto-immunes ou systemiques et cancers n’est pas fortuite et a deja ete decrite.  Our findings identify a metabolic strategy to therapeutically target cancers with genetic or pharmacologic activation of the Nrf2 antioxidant response pathway by restricting exogenous sources of NEAAs.  The most common myths and misconceptions about cancers in Northern Nigeria include the following: people get cancers from mystical sources originating in the forests or bush; western medication or hospital treatment worsens cancers; and, witchcraft can be used to transmit cancers to people.  Differences in the metabolism of cancer cells or cancer stem cells (CSCs) as compared to normal cells have provided avenues to safely target cancers.  Furthermore, the risk of lung cancer in the subjects with early-onset cancers (age <50 years) was higher than the later-onset cancers (age ≥50 years), especially in individuals with family history of liver cancer (OR 9.  In all, 138 breast cancer (BC) cases, 34 colorectal cancer (CRC) and 19 multiple early-onset cancers were included.  Pathogenic germline TP53 variants predispose to a wide range of early onset cancers, often recognized as the Li‐Fraumeni syndrome (LFS).  As a consequence, therapeutic targeting of such compensatory mechanisms is likely to preferentially target cancers with high levels of replication stress and may prove useful in potentiating chemotherapeutic approaches that exert their effects by interfering with DNA replication.  10021Background: The role of population-based newborn genetic testing to identify infants at high risk of childhood-onset cancers has not been studied, despite the availability of cancer surveillan.  Finally, we narrowed down the target cancers to the six most common types and achieved up to 94% accuracy.  The alteration of T-cell specificity by genetically modifying them to express well-characterized, high-affinity TCRs allows ACT to target cancers with normal extracellular surface markers presented in the context of the Major Histocompatibility Complex (MHC) proteins.  Malignancy often arises from sophisticated defects in the intricate molecular mechanisms of cells, rendering a complicated molecular ground to effectively target cancers.